154 related articles for article (PubMed ID: 27746700)
1. Effects of maternal symptom ratings and other clinical features on short-term treatment response to OROS methylphenidate in children and adolescents with ADHD in a naturalistic clinical setting.
Tasgin EC; Oner O; Yurtbasi P; Munir K
Klinik Psikofarmakol Bulteni; 2016; 26(2):126-133. PubMed ID: 27746700
[TBL] [Abstract][Full Text] [Related]
2. Effect of Ferritin on Short-Term Treatment Response in Attention Deficit Hyperactivity Disorder.
Oner P; Oner O; Cop E; Munir KM
Klinik Psikofarmakol Bulteni; 2012; 22(4):325-331. PubMed ID: 28804252
[TBL] [Abstract][Full Text] [Related]
3. Switching from Methylphenidate-Immediate Release (MPH-IR) to Methylphenidate-OROS (OROS-MPH): A Multi-center, Open-label Study in Korea.
Kim BN; Kim YN; Cheong US; Kim JW; Hwang JW; Shin MS; Cho SC;
Clin Psychopharmacol Neurosci; 2011 Apr; 9(1):29-35. PubMed ID: 23430964
[TBL] [Abstract][Full Text] [Related]
4. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
Yılmaz S; Bilgiç A; Hergüner S
J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
[TBL] [Abstract][Full Text] [Related]
5. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
7. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
8. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
[TBL] [Abstract][Full Text] [Related]
9. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
10. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
Remschmidt H; Hoare P; Ettrich C; Rothenberger A; Santosh P; Schmidt M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE; Medori R
Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):297-304. PubMed ID: 16220213
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
Chronis-Tuscano A; Seymour KE; Stein MA; Jones HA; Jiles CD; Rooney ME; Conlon CJ; Efron LA; Wagner SA; Pian J; Robb AS
J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
[TBL] [Abstract][Full Text] [Related]
12. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
[TBL] [Abstract][Full Text] [Related]
14. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effect of methylphenidate by computed tomography, electroencephalography, neuropsychological tests, and clinical symptoms in children with attention-deficit/hyperactivity disorder: A prospective cohort study.
Yildiz Oc O; Agaoglu B; Sen Berk F; Komsuoglu S; Karakaya I; Coskun A
Curr Ther Res Clin Exp; 2007 Nov; 68(6):432-49. PubMed ID: 24692774
[TBL] [Abstract][Full Text] [Related]
17. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
18. An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.
Zheng Y; Liang JM; Gao HY; Yang ZW; Jia FJ; Liang YZ; Fang F; Li R; Xie SN; Zhuo JM
Chin Med J (Engl); 2015 Nov; 128(22):2988-97. PubMed ID: 26608976
[TBL] [Abstract][Full Text] [Related]
19. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
